According to Zacks, “Johnson Matthey Plc is a speciality chemicals company focused on its core skills in catalysis, precious metals, fine chemicals and process technology. Its principal activities comprise manufacture of autocatalysts, heavy duty diesel catalysts and pollution control systems, catalysts and components for fuel cells, catalysts and technologies for chemical processes, fine chemicals, chemical catalysts and active pharmaceutical ingredients. The Company also engages in the marketing, refining, and fabrication of precious metals. Its environmental technologies include emission control technologies, process technologies and fuel cells. Its precious metals products include platinum, noble metals, catalysts, chemicals and refining and colour technologies. Its fine chemicals include macfarlan smith, pharmaceutical materials and services and research chemicals. Johnson Matthey Plc is headquartered in London, U.K. “
A number of other equities analysts have also weighed in on JMPLY. Barclays reiterated an “underweight” rating on shares of Johnson Matthey in a research report on Monday, September 20th. UBS Group restated a “sell” rating on shares of Johnson Matthey in a research report on Wednesday, October 13th. Morgan Stanley restated an “overweight” rating on shares of Johnson Matthey in a research report on Monday, October 18th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Johnson Matthey in a research report on Monday, October 4th. Finally, Panmure Gordon lowered shares of Johnson Matthey from a “hold” rating to a “sell” rating in a research report on Tuesday, October 19th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, Johnson Matthey presently has an average rating of “Hold” and an average price target of $994.65.
Shares of JMPLY traded down $1.89 during mid-day trading on Tuesday, reaching $57.93. The stock had a trading volume of 1,066 shares, compared to its average volume of 1,812. Johnson Matthey has a 12 month low of $57.93 and a 12 month high of $95.72. The business has a fifty day moving average of $71.66 and a 200 day moving average of $81.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.85 and a current ratio of 1.35.
About Johnson Matthey
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
See Also: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Johnson Matthey, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Johnson Matthey wasn’t on the list.
While Johnson Matthey currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.